Background: Hyperglycemia during corticosteroid and asparaginase therapy for acute lymphoblastic leukemia is a significant side effect that is usually treated with insulin. Metformin is an oral antidiabetic biguanide that may cause metabolic acidosis and liver enzyme abnormalities of possible concern in patients receiving chemotherapy.
M edication-induced diabetes mellitus, defined as glucose intolerance, which leads to hyperglycemia, occurs commonly in children treated for acute lymphoblastic leukemia (ALL) with a combination of corticosteroids and asparaginase. 1 The mechanism is felt to be due to insulin resistance from glucocorticoids plus reduced insulin secretion in response to hyperglycemia and possibly reduced number of insulin receptors from asparaginase. 2, 3 Treatment with either single agent corticosteroids or single agent asparaginase causes significant hyperglycemia in about 1% of patients and the combination synergistically increases glucose intolerance. Risk factors for hyperglycemia included age over 10 years, Down syndrome, obesity, and a family history of diabetes mellitus. The frequency of hyperglycemia increases when there is >1 risk factor. 1 Pui et al observed hyperglycemia during remission induction in 41 (9.7%) of 421 pediatric patients who received the combination of prednisone and asparaginase for ALL. 4 In 39 of the 41 patients, hyperglycemia developed within a week of the first dose of asparaginase. Koltin et al 5 observed a 15.7% incidence of medication-induced diabetes in patients with ALL. They confirmed the previously described association with age >10 years and Down syndrome. They also noted an increased risk with central nervous system involvement at diagnosis. In contradistinction to earlier reports, they did not find any association with body mass index. In multivariate analysis, age >10 years and central nervous system involvement were significantly associated with medication-induced diabetes.
Transient hyperglycemia during induction chemotherapy for ALL is even more frequent, affecting up to 20% of patients, as reported by Lowas and colleagues. 6, 7 Overt hyperglycemia during ALL induction has been associated with decreased relapse-free survival and overall survival. 8 Traditionally, insulin therapy had been used for treatment of symptomatic hyperglycemia in patients with ALL. Insulin requires subcutaneous administration and frequent monitoring of the blood glucose level to prevent hypoglycemia. Subcutaneous injections and finger pricks for glucose monitoring required with insulin therapy may add more discomfort and stress to the child and family.
Metformin, an oral antidiabetic agent is not associated with hypoglycemia, a known concern with insulin. In addition, metformin has many interesting off-target effects that may be beneficial to patients with malignancies. A number of studies have shown a lower incidence of malignancy in diabetic patients treated with prolonged metformin. 9 Diabetic breast cancer patients on metformin show an increased pathologic complete response after 21 weeks of neoadjuvant chemotherapy than diabetic breast cancer patients not on metformin. 10 This may be due to the inhibition of AMPK by metformin and its downstream targets such as mTOR or AKT. 11 Targeting mTOR has shown benefit in childhood ALL. 12 In addition, metformin may protect patients from anthracycline cardiotoxicity. 13, 14 The anthracyclines doxorubicin and daunorubicin are frequently given in conjunction with corticosteroids and asparaginase. Thus, patients may be placed on metformin therapy for hyperglycemia at the time they are receiving cardiotoxic anthracyclines. The role of oral antidiabetics in adults with steroid-induced diabetes is felt to be limited because of slow action and a potential for side effects. 15 A comprehensive literature review did not reveal any reports on the use of metformin or other oral antidiabetic agents in pediatric patients with cancer or for medication-induced diabetes in children or adults with leukemia or lymphoma.
MATERIALS AND METHODS

Patients
Patients with ALL who developed hyperglycemia from corticosteroids with or without asparaginase and received metformin with or without insulin were identified from the electronic medical record data warehouse and pharmacy database.
Glucose levels were monitored periodically while patients were on corticosteroid courses lasting longer than 7 days, which typically occurs during remission induction or relapse reinduction. At our institution, at the onset of hyperglycemia, if the patient is on intravenous fluids, dextrose is removed and the glucose level is monitored at least once daily. No attempt was made to control the patient's diet, as this is impractical because of the appetite stimulation by corticosteroids. If patients were not on intravenous fluids or hyperglycemia persisted after removal of dextrose, immediate release metformin either once or twice daily, depending on the dose, was instituted.
After obtaining Institutional Review Board approval, the following data was retrospectively collected for analysis: name; medical record number; date of birth; sex; race/ethnicity; leukemia diagnosis date; treatment protocol; steroid used; asparaginase used; date metformin and/or insulin started and ended; metformin dose; and family history of diabetes mellitus. Serum glucose levels were obtained during metformin and/or insulin therapy. All laboratory tests performed during, immediately before, and immediately after metformin administration were reviewed to assess toxicity. No special laboratory monitoring outside of that routinely done during ALL therapy was carried out.
Pediatric endocrinologists were consulted for the administration of metformin therapy and management of hyperglycemia needing intervention with insulin. In some situations, the consulting endocrinologist elected to start insulin either before or simultaneously with metformin.
Data Analysis
Data were entered into SPSS for tabulation and descriptive analyses.
RESULTS
Clinical Characteristics and Leukemia Therapy
Patient demographics including age, weight, sex, ethnicity, and ALL phenotype are outlined in Table 1 . The median age of 11 years in the 12 first remission patients was significantly higher than that of pediatric ALL patients, which peaks between 2 and 5 years of age. The distribution of sex, ethnicity, and ALL phenotype were typical for our patient population. Family history for diabetes in parents, siblings, and grandparents was available in 15 of the patients, of which 9 (60%) were positive. Documentation of diabetes type in the family member was only available in 3 (type 1 in UPN 7; type 2 in UPN 12 and 14). The phase of treatment and corticosteroid and asparaginase use are also documented in Table 1 . All patients were being treated for initial induction (n = 12) or relapse reinduction (n = 5). All but one were receiving a chemotherapeutic corticosteroid (dexamethasone, n = 11 or prednisone, n = 5). UPN 16 was receiving megesterol (Megace) for appetite stimulation, which occasionally may result in hyperglycemia, especially at high doses. 16 Pegaspargase was used in 15 patients and was the only asparaginase product used. Two patients did not receive pegaspargase because of allergy and were not able to receive erwinase because of lack of FDA approval at the time. to 64 mg/kg/d). The median number of days of metformin treatment was 6 (range, 2 to 46). Usually metformin was continued until after the corticosteroid therapy was completed. There were no episodes of hypoglycemia. The glucose level was controlled with metformin alone in 12 patients without the need for insulin. Four patients (UPN 4, 8, 10, 16) received insulin before or concomitantly with metformin. In 1 patient (UPN 15), metformin failed to control the glucose level, and insulin was administered. The reason for insulin use varied. Tumor lysis-associated electrolyte disturbance and renal dysfunction in UPN 8 was considered a contraindication to initial metformin; therefore, insulin was started and metformin was added after metabolic abnormalities resolved. In the other 3 patients (UPN 4, 10, 16), the serum glucose level at insulin initiation was over 400 mg/dL and the consulting endocrinologist recommended insulin be used initially based on past practices. Three of the patients (UPN 8, 10, 15) started on insulin were weaned off insulin to metformin alone. Only UPN 4 required insulin to be continued for glucose control. The only patient to fail metformin therapy was UPN 15. This patient was started on 250 mg bid of metformin for a glucose level of 338 mg/mL, which subsequently increased to 906 mg/mL after 6 days, during which metformin was increased to 500 mg bid. Nine days from the start of metformin, the glucose level was 522 mg/mL; therefore, insulin was started and metformin dose was increased to 500 mg tid with rapid resolution of hyperglycemia. The insulin was discontinued and metformin was continued at 500 mg bid until the patient had completed his end of induction steroid taper. In the 12 patients who did not receive insulin, 8 had excellent control with metformin alone with no blood glucose levels over 200 mg/dL from the day after metformin was started.
Hyperglycemia Treatment
Interestingly, UPN 6, who was diagnosed before we initiated the use of metformin for hyperglycemia in ALL patients at our hospital, required insulin during induction therapy for hyperglycemia. This patient developed hyperglycemia during relapse reinduction, and metformin alone effectively controlled hyperglycemia without the need for insulin.
Observed Toxicities
As part of routine management during induction therapy for ALL, patient undergo frequent testing of blood counts and chemical analyses including electrolytes and liver function tests. Table 3 details the results of anion gap, creatinine, bilirubin, and alanine aminotransferase levels in these patients. Anion gap was used a marker of lactic acidosis. Two patients (UPN 15 and 16) had mild elevations of creatinine and anion gap while on metformin or shortly after it was discontinued. At the time, both had extreme glucose level elevations that peaked at 906 and 1092 mg/dL, respectively, and were treated with insulin accordingly. It is likely that the metabolic abnormalities were related to ketoacidosis and were not a consequence of metformin. UPN 1 had a mild elevation of total bilirubin level and 5 patients (UPN 1, 3, 4, 7, 8 ) had mild elevations of alanine aminotransferase levels. These elevations were of low grade by common toxicity criteria v3.0 17 and are frequently seen at the time of ALL diagnosis or during induction chemotherapy. 18, 19 Thus, we could find no conclusive evidence of toxicity related to metformin use.
DISCUSSION
Concern for Using Metformin in Patients With Leukemia
When we started using metformin for hyperglycemia in ALL patients, there was a concern about increased toxicity due to concomitant chemotherapy or comorbid conditions. This was not observed in any patient. In fact, there Lalau in a recent comprehensive review of metformininduced lactic acidosis concluded that it is a rare complication with an excellent prognosis when the drug is stopped. He states, "Given the established efficacy of metformin, it would be paradoxical to deny the majority of patients with long established diabetes access to metformin because of the high number of contraindications to this drug, when the same pharmacological mechanisms that relate to lactic acidosis would probably result in protective benefits to these patients." 21 In adults with diabetes, acidosis was rare and never directly attributed to metformin. 22 In cases of metformin overdose, acidosis was seen in 1.6% and hypoglycemia in 2.8% of patients. 23 In that study, children under the age of 12 years experienced few adverse outcomes, suggesting that younger patients are at lower risk for metformin toxicity during an overdose, which also may be true during therapeutic use. Recent reviews suggest that metformin does not appear to cause or exacerbate liver injury, and hepatotoxicity is not a contraindication for its use. 24 As this was an exploratory study, we did not have a formal clinical pathway or strict criteria for what level of glucose would warrant the use of metformin and what level would require insulin. However, based on its lack of toxicity, we would suggest instating metformin for patients with a blood glucose level r300 mg/dL without significant comorbidities such as tumor lysis syndrome, ketonuria, or significant dehydration. For patients with a blood glucose level >300 mg/mL or other comorbidities, a short course of insulin followed by metformin would be an option. We do not feel elevated hepatic transaminases, which can be seen in ALL patients, are a contraindication to use metformin.
CONCLUSIONS
In our experience, metformin is safe and effective for controlling hyperglycemia induced from corticosteroids and asparaginase and may obviate or reduce the need for insulin with its attendant difficulties of hypoglycemia, subcutaneous administration, and frequent blood sugar monitoring. In addition, metformin in combination with chemotherapy may theoretically improve the worse prognosis seen in ALL patients who experience hyperglycemia by potentially inhibiting mTOR, an active target in leukemia cells. As cardiotoxicity is a significant concern in ALL survivors, 25 the additional benefit of possible reduction in this risk would also be a welcome benefit of metformin.
